SSG
TEVA icon

Summit Securities Group’s Teva Pharmaceuticals TEVA Stock Holding History

Summit Securities Group’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-216
Closed -$249K – 865
2021
Q1 		$249K Buy
+216
New +$2.48K 0.03% 485
2019
Q3 		– Sell
-115
Closed -$106K – 405
2019
Q2 		$106K Buy
+115
New +$1.39K 0.01% 310
2016
Q1 		– Sell
-48
Closed -$5K – 325
2015
Q4 		$5K Buy
+48
New +$2.97K ﹤0.01% 246

Other funds holding TEVA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $43.8B AUM 42.28% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Summit Securities Group's TEVA Position: Q1 2026 in Review

Summit Securities Group increased its Teva Pharmaceuticals (TEVA) stake by 25% in Q1 2026, buying an estimated $48.3K and bringing the position to 7,500 shares worth $226K. The position accounts for 0.03% of the portfolio, ranked #220.

Summit Securities Group first reported a position in TEVA in Q2 2013 and has held it in 15 quarters since. The position peaked at $2.09M in Q3 2014. 650 funds tracked by Wall St. Rank hold TEVA as of Q1 2026.

  • Summit Securities Group held 7,500 shares of Teva Pharmaceuticals worth $226K as of Q1 2026.
  • Summit Securities Group bought 1,500 Teva Pharmaceuticals shares in Q1 2026, an estimated $48.3K.
  • Teva Pharmaceuticals made up 0.03% of Summit Securities Group's portfolio in Q1 2026, its #220 holding.
  • Summit Securities Group first reported a position in Teva Pharmaceuticals in Q2 2013 and has held it in 15 quarters since.
  • Summit Securities Group's Teva Pharmaceuticals position peaked at $2.09M in Q3 2014.
  • 650 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2026.

Based on Summit Securities Group's 13F filing for Q1 2026, filed 30 Apr 2026.